A Phase 4 clinical trial involving goserelin was updated on September 2, 2026, with a status change to terminated. The study, titled "Contributions to Hypertension With Androgen Deprivation Therapy," was registered under identifier NCT05700903.
The trial was designed as a Phase 4 study examining androgen deprivation therapy, which includes goserelin, in relation to hypertension. According to the available record, the trial status is now listed as terminated. No additional details regarding the reason for termination were provided in this update.
Because the trial is marked terminated, no results have been reported as part of this update. This brief reflects only the status change and trial title as recorded. Readers should not interpret this update as indicating any specific safety finding or efficacy outcome, since the event data does not include results or a stated rationale for termination.
Goserelin is an approved compound used in the context of androgen deprivation therapy. Updates to trials involving approved compounds are tracked as part of ongoing clinical research monitoring. For more background on goserelin, readers can consult the compound overview.